MeSH D006937 - hypercholesterolemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| 3M | Fenofibrate | Duraprep |  | 2006-09-29 |  |  |
| Fenofibrate, Chlorhexidine | Soluprep | 2029-07-26 | 2018-08-08 |  |  | |
| AbbVie | Niacin | Niaspan Titration Starter Pack |  | 1997-07-28 |  |  |
| Fenofibrate | Tricor |  | 1993-12-31 | $606 M | Q3/12-Q3/13 | |
| Accord Healthcare | Atorvastatin | Atorvastatin |  | 2018-03-30 |  |  |
| Ezetimibe | Ezetimibe |  | 2018-10-26 |  |  | |
| Pravastatin | Pravastatin |  | 2016-11-17 |  |  | |
| Rosuvastatin | Rosuvastatin |  | 2016-10-31 |  |  | |
| Simvastatin | Simvastatin |  | 2008-02-26 |  |  | |
| Agnitio | Atorvastatin | Atorvastatin |  | 2021-09-02 |  |  |
| Ajanta Pharma | Fenofibrate | Fenofibrate |  | 2018-07-23 |  |  |
| Alembic Pharmaceuticals | Fenofibrate | Fenofibrate |  | 2019-08-09 |  |  |
| Alkem Laboratories | Atorvastatin | Atorvastatin |  | 2018-12-21 |  |  |
| Colesevelam | Colesevelam |  | 2018-10-05 |  |  | |
| Ezetimibe | Ezetimibe |  | 2017-12-21 |  |  | |
| Ezetimibe, Simvastatin | Ezetimibe Simvastatin |  | 2017-12-22 |  |  | |
| Rosuvastatin | Rosuvastatin |  | 2017-03-21 |  |  | |
| Allergan | Colesevelam | Colesevelam |  | 2020-09-02 |  |  |
| Ezetimibe | Ezetimibe |  | 2017-06-12 |  |  | |
| Ezetimibe, Simvastatin | Ezetimibe Simvastatin |  | 2017-04-26 |  |  | |
| Lovastatin | Lovastatin |  | 2001-12-17 |  |  | |
| Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Ergocalciferol, Vitamin a, Biotin, Niacinamide, Pyridoxine, Riboflavin, Thiamine | Mvc |  | 1985-08-08 |  |  | |
| Niacin | Niacin |  | 1982-01-01 |  |  | |
| Pravastatin | Pravastatin |  | 2006-10-23 |  |  | |
| Rosuvastatin | Rosuvastatin |  | 2016-04-29 |  |  | |
| Simvastatin | Simvastatin |  | 2006-12-20 |  |  | |
| Althera Pharmaceutical | Ezetimibe, Rosuvastatin | Roszet | 2033-05-01 | 2021-03-23 |  |  |
| Amgen | Evolocumab | Repatha |  | 2015-08-27 | $2,222 M | Y2024 |
1
2
3
4
5
6
...
13
>
Clinical Trials
Historical Success Rate
Phase 1
65%17/26
Phase 2
59%26/44
Phase 3
68%50/73
Approved: 30Overall Success rate: 26%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
9
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use